Clinical Trial

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Protocol Amendment History 1 change
minor Completion pushed: 2026-05-01 -> 2026-12-31 2026-07-14
Trial Details
NCT Number NCT03940703
Lead Sponsor EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Non-small Cell Lung Cancer
Enrollment 140 participants
Start Date 2019-09-19
Primary Completion 2023-05-11 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13